Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, acc ...

The link between hepatic fat and IPFD observed in young individuals with good cardiometabolic health diminished in older ...

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

USA: A recent study, published in JAMA Network Open as a research letter, highlights a significant link between anti-obesity ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

New Jerseyans are worried about the cost of services, unexpected medical bills, monthly premiums and prescription drug costs, ...

Ozempic is only approved here for diabetes management. Meanwhile, Wegovy, a new brand of semaglutide (the active ingredient ...

BioNxt Solutions Inc. ("BioNxt" or the "Company") , a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) ...

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.

Obesity and cardiovascular risk factors accelerate brain volume loss, with males experiencing earlier and more significant ...

Tirzepatide, a weight loss drug, shows promise in preventing diabetes by improving insulin sensitivity and aiding in weight ...